Kick off an exceptional day of learning by joining Psych Congress Regionals expert faculty for a brief roundtable discussion about the state of mental healthcare – what’s here, what’s new, and what’s next. Gain unique perspectives on everything from disease-states to the work-life-balance of today’s clinicians and blooming opportunities in treatment.

Supported by an educational grant from Tonix Pharmaceuticals.

Fibromyalgia often hides behind the depression, anxiety, and sleep complaints psychiatric clinicians see daily. This masterclass covers how to recognize and diagnose FM using current ACR criteria and practical screening tools, how to select among established and newly approved therapies, and how to communicate the diagnosis in a way that validates patients and strengthens engagement and multidisciplinary care.

Innovation Theaters are informational sessions designed to complement your educational experience by further enhancing your knowledge and confidence of disease states or products. No CE credits are offered at these programs.

Supported by an independent educational grant from Johnson & Johnson.

Many psychiatric patients receive multiple medications to manage comorbid conditions, yet polypharmacy increases the risk of adverse effects, drug interactions, and nonadherence. This session will help attendeess develop a critical approach to deprescribing, teaching them how to identify unnecessary medications, streamline regimens, and use pharmacogenetics to guide personalized treatment.

Join expert panelists from sessions throughout this section of the day as they answer your most pressing and popular questions from sessions so far.

Innovation Theaters are informational sessions designed to complement your educational experience by further enhancing your knowledge and confidence of disease states or products. No CE credits are offered at these programs.

Supported by educational grants from Neurocrine Biosciences, Inc and Teva Pharmaceuticals.

Advances in schizophrenia treatment are expanding beyond traditional dopamine D2 receptor antagonism, with muscarinic receptor–based therapies offering a novel mechanism of action. This session will compare muscarinic approaches with conventional antipsychotics, and participants will develop skills in interpreting clinical trial data for both approved and investigational muscarinic agents, including the use of appropriate efficacy endpoints and understanding regulatory context. The session will also address practical considerations for incorporating these therapies into clinical practice with emphasis on patient-centered strategies to optimize adherence and outcomes. Attendees will leave equipped to critically evaluate and thoughtfully integrate emerging muscarinic-based treatments into schizophrenia care.

Supported by an educational grant from Bristol-Myers Squibb.

Join expert panelists from sessions throughout this section of the day as they answer your most pressing and popular questions from sessions so far.

Dive into real-world, complex clinical cases in this panel discussion among our experts. In this session, Dr. Brittany Albright will share real-world examples of clinical cases with our faculty members and will discuss the challenges and most effective approaches to each.

Close out an exceptional day of learning by joining Psych Congress Regionals expert faculty for a brief roundtable discussion about the state of mental healthcare – what’s here, what’s new, and what’s next. Gain unique perspectives on everything from disease-states to the work-life-balance of today’s clinicians and blooming opportunities in treatment.

Kick off an exceptional day of learning by joining Psych Congress Regionals expert faculty for a brief roundtable discussion about the state of mental healthcare – what’s here, what’s new, and what’s next. Gain unique perspectives on everything from disease-states to the work-life-balance of today’s clinicians and blooming opportunities in treatment.

ADHD can present differently across the lifespan, and comorbidities and differences in symptom expression can complicate timely diagnosis. This session reviews evidence-based diagnostic approaches and the design, pharmacology, and clinical evidence behind newer stimulant formulations and delivery systems. Faculty will examine how age, comorbidities, adherence, and dosing needs inform treatment selection. Through shared decision-making, participants will explore how to align treatment with each patient’s preferences and functional goals.

Supported by an educational grant from Collegium Pharmaceutical, Inc.

Innovation Theaters are informational sessions designed to complement your educational experience by further enhancing your knowledge and confidence of disease states or products. No CE credits are offered at these programs.

Supported by an independent educational grant from Johnson & Johnson.

Insomnia is one of the most common yet underdiagnosed conditions in psychiatric practice, often exacerbating mood, anxiety, and psychotic disorders. This session will provide a foundational approach to insomnia assessment and treatment, helping psychiatrists navigate the bidirectional relationship between sleep and mental health. Faculty will explore key diagnostic considerations, pharmacologic and non-pharmacologic interventions, and practical strategies for integrating sleep-focused care into psychiatric practice.

Join expert panelists from sessions throughout this section of the day as they answer your most pressing and popular questions from sessions so far.

Innovation Theaters are informational sessions designed to complement your educational experience by further enhancing your knowledge and confidence of disease states or products. No CE credits are offered at these programs.

Supported by an educational grant from Lilly. Alcohol use disorder (AUD) is a prevalent and often undertreated condition that exists along a spectrum of severity, yet stigma and inconsistent assessment continue to limit optimal care. This session will review the medical model of AUD and its role in improving recognition, reducing stigma, and guiding evidence-based treatment. Participants will gain practical skills in implementing validated screening tools and assessment strategies to support accurate diagnosis in diverse clinical settings. The session will also evaluate current behavioral and pharmacologic treatments, including best practices for medication-assisted treatment (MAT) selection, initiation, and maintenance. Finally, attendees will explore patient-centered, collaborative approaches to overcoming common barriers to effective AUD management. Clinicians will leave equipped with actionable strategies to enhance outcomes for patients across the AUD severity spectrum.

Once relegated to the margins of medicine, psychedelic compounds are re-emerging as potential tools in psychiatric care. This session traces the evolution of psychedelics from prohibition to evidence-based investigation and cautious clinical integration. Attendees will review current data on efficacy and safety, understand approved and investigational indications, and explore practical considerations as well as address regulatory status and future directions.

Join expert panelists from sessions throughout this section of the day as they answer your most pressing and popular questions from sessions so far.

Dive into real-world, complex clinical cases in this panel discussion among our experts. In this session, Dr. Rakesh Jain will share real-world examples of clinical cases with our faculty members and will discuss the challenges and most effective approaches to each.

Close out an exceptional day of learning by joining Psych Congress Regionals expert faculty for a brief roundtable discussion about the state of mental healthcare – what’s here, what’s new, and what’s next. Gain unique perspectives on everything from disease-states to the work-life-balance of today’s clinicians and blooming opportunities in treatment.